# Vivan Therapeutics Clears UAE Approvals to Start TuMatch Colorectal Cancer Study at Burjeel

> Vivan Therapeutics has all regulatory approvals to begin a TuMatch clinical registration study at Burjeel Cancer Institute in Abu Dhabi.

- Published: 2026-11-12T11:32:16+00:00
- Section: Regulation & Approvals
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-12/vivan-therapeutics-tumatch-burjeel-approval
- Source: [EIN Presswire](https://www.einnews.com/pr_news/956232035/vivan-therapeutics-set-to-begin-tumatch-clinical-registration-study-at-burjeel-cancer-institute-abu-dhabi)

## Key takeaways

- Vivan Therapeutics received all regulatory approvals to begin a clinical registration study of TuMatch at Burjeel Cancer Institute in Abu Dhabi.
- The prospective study will enroll at least 10 colorectal cancer patients and is led by Prof. Humaid Al Shamsi.
- Data from the study is intended to support reimbursement discussions and the company's CE mark and FDA submissions for TuMatch.

Vivan Therapeutics said on November 12, 2026 that it has received all regulatory approvals to begin a clinical registration study of its TuMatch clinical decision support software at Burjeel Cancer Institute in Abu Dhabi. The prospective study will enroll at least 10 colorectal cancer patients, according to [EIN Presswire](https://www.einnews.com/pr_news/956232035/vivan-therapeutics-set-to-begin-tumatch-clinical-registration-study-at-burjeel-cancer-institute-abu-dhabi).

## How the TuMatch Study at Burjeel Will Work

[Vivan Therapeutics](https://akta.pro/company-profiles/0002i2e/vivan-therapeutics) is a precision oncology company that builds AI-enabled tools to match cancer patients to treatments. The study will be led by Prof. Humaid Al Shamsi at [Burjeel Cancer Institute](https://akta.pro/company-profiles/00bvih5/burjeel-cancer-institute), part of Burjeel Medical City. Burjeel Breast Center, which sits within Burjeel Cancer Institute, provides breast cancer care from screening through treatment, GulfNews reported on October 22, 2026.

TuMatch analyses a patient's tumour genomic profile against Vivan's proprietary drug-response dataset, generated with an in vivo Drosophila "avatar" screening platform developed with Mount Sinai Medical Center, alongside published clinical evidence. The output is a ranked set of therapeutic options for the treating oncologist, aimed at patients who have exhausted or are unlikely to benefit from standard-of-care regimens. The study is also designed to capture health economics and value-based care data intended to support reimbursement discussions with payers.

Dr Nahuel Villegas, Chief Scientific Officer of Vivan Therapeutics, said: "Colorectal cancer is notoriously hard to treat, and particularly challenging for patients with activating KRAS mutations, who often have no effective standard-of-care options left." Laura Towart, Vivan Founder and CEO, said: "This approval takes TuMatch from a validated platform to a tool being used in live clinical decision-making."

## Vivan's Funding and Research Partnerships

Vivan Therapeutics has four funding rounds on record, including a seed round of $3.7 million in September 2021 and a pre-seed round of $924,770 in March 2019 led by SFC Capital, according to akta.pro [company records](https://akta.pro/company-data). The same records list total funding of $4.6 million at Series A stage, with the last round dated December 19, 2022. In November 2025 the company entered a research partnership with the MRC Laboratory of Medical Sciences to study how KRAS mutations, diabetes and diet influence chemotherapy responses using its in vivo fruit fly screening platform.

## Earlier Steps Toward the Abu Dhabi Study

On October 23, 2026, EIN Presswire reported that Vivan Therapeutics had received regulatory approvals to begin the TuMatch clinical registration study at Burjeel Cancer Institute in Abu Dhabi. On September 16, 2026, The Pharma Letter reported that Vivan and Ad Atomica announced a discovery collaboration combining Vivan's genotype-resolved cancer screening data with Ad Atomica's AI-driven small molecule design platform.

## What Comes After the Abu Dhabi Site

The Abu Dhabi study forms part of a broader clinical programme that includes a planned multicentre study in pancreatic and other GI cancers with sites in Europe and the GCC. Data from these studies will support the company's CE mark and FDA submissions for TuMatch.

## Companies in this story

- [VIVAN Therapeutics company profile](https://akta.pro/company-profiles/0002i2e/vivan-therapeutics) · website: https://www.vivantx.com
- [Burjeel Cancer Institute company profile](https://akta.pro/company-profiles/00bvih5/burjeel-cancer-institute) · website: https://burjeelcancerinstitute.org

---
News for Agent · https://newsforagent.com/llms.txt